WHITE PAPER
Half-Year Review of 2023
IQVIA Pharma Deals
Oct 11, 2023

The Pharma Deals H1 Review of 2023 provides an insightful overview of deal activity in 2023 so far, as well as an outlook for H2. 

Key information provided includes the following:

  • Top M&A and partnership deals in H1 2023
  • Deal activity by therapeutic area and development phase
  • Deal value analysis of M&A, licensing and R&D deals
  • Deal activity rankings of the top pharmaceutical companies


Report key highlights:

  • Amid macroeconomic headwinds and continued market volatility, the number of M&A deals announced by life science companies dropped 28% from H1 2022 to H1 2023. 
  • As companies are becoming more selective in the types of assets they invest in, licensing deal volume in the life sciences sector fell 31% from H1 2022 to H1 2023. 
  • Dropping below pre-pandemic levels, collaborative alliance activity in H1 2023 fell by 54% from H1 2022 to H1 2023.
  • Oncology was once again the most popular therapy area for dealmaking in the life sciences sector in H1 2023, although deal volume was reduced in line with over

Fill in your details on the left, to download the whitepaper immediately.

If you would like to learn more about Pharma Deals and see how the solution can benefit you, please click here.

Related solutions

Contact Us